Intravenous proton pump inhibitor therapy: A rationale for use

Reviews in Gastroenterological Disorders

Volumn 5, Issue SUPPL. 2, 2005, Pages

  Armstrong, David ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Acid related disorders; Gastroesophageal reflux disease; Intravenous administration; Peptic ulcer disease; Proton pump inhibitors; Stress related mucosal disease; Upper gastrointestinal bleeding

Indexed keywords

ANTACID AGENT; CIMETIDINE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

AREA UNDER THE CURVE; ARTICLE; ASPIRATION PNEUMONIA; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS; PEPTIC ULCER; PREOPERATIVE TREATMENT; RISK FACTOR; RISK REDUCTION; STOMACH PH; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; GASTROESOPHAGEAL REFLUX; HUMANS; INJECTIONS, INTRAVENOUS; OMEPRAZOLE; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PROTON PUMPS; SULFOXIDES;

EID: 29444460869     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Chiba N, de Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810.
2. Guda N, Noonan M, Kreiner J, et al. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol. 2004;99:1233-1237.
3. Kaplan GG, Bates D, McDonald D, et al. Inappropriate use of intravenous proton pump inhibitors: problem extent and cost implications. Am J Gastroenterol. 2002;97:S236.
4. Bair FD, Armstrong D, Zhou P. Intravenous acid suppression - appropriateness of use in a tertiary care setting [abstract]. Gastroenterology. 2001;120:A730.
5. Cornish P, Papastergiou J, Saibil F. Audit of PV pantoprazole: patterns of use and compliance with guidelines. Can J Hosp Pharm. 2002;55: 20-26.
6. Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the S-isomer of omeprazole - a review. Clin Pharmacokinet. 2001;40:411-426.
7. Hartmann M, Ehrlich A, Fuder H, et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther. 1998;12:1027-1032.
8. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000;95:626-633.
9. Kovacs TOG, Lee CG, Chiu YL, et al. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment Pharmacol Ther. 2004;20:883-889.
10. Wilder-Smith CH, Bondarov P, Lundgren M, et al. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur J Gastroenterol Hepatol. 2005;17:191-197.
11. Bair FD, James C, Armstrong D. Maximal acid suppression: oral vs. intravenous pantoprazole. Gastroenterology. 2002;122:A476-A477.
12. Miner PB Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98:2616-2620.
13. Freston J, Chiu Y, Pan W, et al. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol. 2001;96:2058-2065.
14. Armstrong D, Bair D, James C, et al. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther. 2003;18:705-711.
15. Wilder-Smith CH, Röhss K, Bondarov P, et al. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment Pharmacol Ther. 2004;20:1099-1104.
16. Armstrong D. Gastric pH-the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther. 2004;20(suppl 5):19-26.
17. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion. 1992;51(suppl 1):59-67.
18. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000;118:696-704.
19. Metz DC, Forsmark C, Lew EA, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol. 2001;96:3274-3280.
20. Wilder-Smith C, Lind T, Lundin C, et al. Comparison of esomeprazole (20, 40, 80 mg) versus lansoprazole (15, 30, 60 mg) on intragastric pH in healthy subjects [abstract]. Gastroenterology. 2003;124:A444.
21. Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and pharmaco-kinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther. 2004;20:399-406.
22. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily - a randomized, two-way crossover study. Aliment Pharmacol Ther. 2005;21:963-967.
23. Wurzer H, Schutze K, Bethke T, et al. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology. 1999;46:1809-1815.
24. Schneider H, Van Rensburg C, Schmidt S, et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion. 2004;70:250-256.
25. Warner MA, Warner ME, Weber JG. Clinical significance of pulmonary aspiration during the perioperative period. Anesthesiology. 1993;78: 56-62.
26. Pisegna JR, Martindale RG. Acid suppression in the perioperative period. J Clin Gastroenterol. 2005;39:10-16.
27. Schwartz DJ, Wynne JW, Gibbs CP, et al. The pulmonary consequences of aspiration of gastric contents at pH values greater than 2.5. Am Rev Respir Dis. 1980;121:119-126.
28. Warner MA, Caplan RA, Epstein BS, et al. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures. Available at: http://www.asahq.org/publicationsAndServices/npoguide.html. Accessed 26 October 2005.
29. Stuart JC, Kan AF, Rowbottom SJ, et al. Acid aspiration prophylaxis for emergency Caesarean section. Anaesthesia. 1996;51:415-421.
30. Vila P, Espachs P, Echevarria V, et al. Acid aspiration prophylaxis in elective biliary surgery: a comparison of omeprazole and famotidine using manually aided gastric aspiration. Anaesthesia. 1994;49:909-911.
31. Hendolin H, Suojaranta-Ylinen R, Alhava E. Effect of single-dose omeprazole and ranitidine on gastric juice acidity and volume in patients undergoing laparotomy. Acta Anaesthesiol Scand. 1993;37:484-487.
32. Bouly A, Nathan N, Feiss P. Comparison of omeprazole with cimetidine for prophylaxis of acid aspiration in elective surgery. Eur J Anaesthesiol. 1993;10:209-213.
33. Nishina K, Mikawa K, Takao Y, et al. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery. Anesth Analg. 2000;90:717-721.
34. Rocke DA, Rout CC, Gouws E. Intravenous administration of the proton pump inhibitor omeprazole reduces the risk of acid aspiration at emergency cesarean section. Anesth Analg. 1994;78:1093-1098.
35. Blatchford O, Davidson LA, Murray W, et al. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ. 1997;315:510-514.
36. Holman RAE, Davis M, Gough KR, Value of centralized approach in the management of haematemesis and melaena: experience in a district general hospital. Gut. 1990;31:504-508.
37. Rockall TA, Logan RFA, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Br Med J. 1995;311:222-226.
38. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994;331:717-725.
39. Green FW Jr, Kaplan MM, Curtis LF, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. Gastroenterology. 1978;74:38-43.
40. Berstad A. Does profound acid inhibition improve haemostasis in peptic ulcer bleeding? Scand J Gastroenterol. 1997;32:396-398.
41. Collins R, Langman MJS. Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage: implications of randomized trials. N Engl J Med. 1985;313:660-666.
42. Levine JE, Leontiadis GI, Sharma VK, Howden CW. Meta-analysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther. 2002;16:1137-1142.
43. Daneshmend TK, Hawkey CJ, Langman MJS, et al. Omeprazole versus placebo for acute upper gastrointestinal bleeding: a randomized, double-blind, controlled trial. Br Med J. 1992;304:143-147.
44. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med. 1997;336:1054-1058.
45. Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol. 1997;32:328-333.
46. Lin HJ, Lo WC, Lee FY, et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med. 1998;158:54-58.
47. Lau JY, Sung JJ, Lee KK et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343:310-316.
48. van Rensburg CJ, Thorpe A, Warren B, et al. Intragastric pH in patients with bleeding peptic ulceration during pantoprazole infusion of 8 mg/hr [abstract]. Gastroenterology. 1997;112:A321.
49. Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: proton pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther. 2005;21:677-686.
50. Barkun A, Fallone CA, Chiba N, et al. A Canadian clinical practice algorithm for the management of patients with nonvariceal upper gastrointestinal bleeding. Can J Gastroenterol. 2004;18:605-609.
51. Barkun AN, Herba K, Adam V, et al. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2004;19:591-600.
52. Erstad BL. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med. 2004;32:1277-1283.
53. Barkun AN, Herba K, Adam V, et al. The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther. 2004;20:195-202.
54. Enns RA, Gagnon YM, Rioux KP, Levy AR. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2003;17:225-233.
55. Gagnon YM, Levy AR, Eloubeidi MA, et al. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health. 2003;6:457-465.
56. Barkun A, Bardou M, Marshall JK, Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing non-variceal upper gastrointestinal bleeding. Ann Intern Med. 2003;139:843-857.
57. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343:310-316.
58. Reilly J, Fennerty MB. Stress ulcer prophylaxis: the prevention of gastrointestinal bleeding and the development of nosocomial infections in critically ill patients. J Pharm Prac. 1998; 11:418-432.
59. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275: 308-314.
60. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med. 1998;338:791-797.
61. Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Crit Care Med. 1999;27:2812-2817.
62. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients: Canadian Critical Care Trials Groups. N Engl J Med. 1994;330:377-381.
63. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol. 1999;94:351-357.
64. Cook DJ, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991;91:519-527.
65. Merki HS, Wilder-Smith CH. Do continuous omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology. 1994; 106:60-64.
66. Phillips JO, Metzler ME, Palmieri TL, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med. 1996;24:1793-1800.
67. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma. 1998;44:527-533.
68. Levy MJ, Seelig CB, Robinson NJ, et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997;42:1255-1259.
69. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm. 1999;56: 347-379.
70. Jung R, MacLaren R. Proton pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother. 2002;36:1929-1937.
71. Barkun AN, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol. 2004;99:1238-1246.
72. Bensoussan K, Fallone CA, Barkun AN, et al. A sampling of Canadian practices in managing upper gastrointestinal bleeding before recent guideline publication: is there room for improvement? Can J Gastroenterol. 2005;19:487-495.